Middle-income countries have gained greater access to a variety of needed cardiovascular medicines, but remain unable to close the gap with wealthy nations, according to a recent analysis of sales data in dozens of countries.
From 2008 to 2018, the compound annual growth rate for all cardiovascular medicines was nearly 10% in middle-income countries compared with almost 1% in high-income nations. As a result, use of those drugs was six times higher in wealthy countries than lower-income nations in 2018, compared to a 15-fold difference a decade earlier.
About the Author Reprints
